ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - ImmunityBio had a remarkable performance in 2025, setting a strong foundation for 2026 [2] Group 1: Company Achievements - The company received approval for its bladder cancer treatment in 2024, which was a significant milestone [3] - In January 2026, ImmunityBio received its J-Code, enabling the commercial team to effectively market their product [4]